Acromegaly Pipeline and Therapeutic Assessment, Drug Development by Companies Reviewed for H1 2017

Published on : May 15, 2017

Albany, New York, May 15, 2017: Recently, increasing prevalence of a hormonal disorder, named ‘Acromegaly’ has forced the research scientists to invent effective treatment for the disease. Due to this, there are several therapeutics developments are in process. A new study, covering the descriptive pharmacological action of the therapeutics, its complete research and development history has been published to the online repository of Market Research Hub (MRH) and titled as “Acromegaly - Pipeline Review, H1 2017”. This study provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The report starts by presenting the acromegaly overview and its therapeutic development under the pipeline overview. Acromegaly is a serious systemic condition caused in over 98% of cases by an adenoma (i.e., benign tumor) of the pituitary gland that secretes excessive growth hormone (GH). It is a hormonal disorder that most commonly occurs in middle-aged men and women. The prevalence of acromegaly is approximately 4,676 cases per million population, and the incidence is 116.9 new cases per million per year. Symptoms include soft tissue thickening of the palms of the hands and soles of the feet, enlargement of hands, feet and head, Arthritis, Oily skin and excessive sweating, Fatigue, Hypertension, Headache etc. Treatment includes surgery, dopamine agonists and growth hormone antagonists. The most common treatment is to remove the adenoma by surgical treatment.

As per the key findings, the clinical diagnosis is confirmed biochemically by an increased serum GH concentration following an oral glucose tolerance test (OGTT) and by detection of increased levels of insulin-like growth factor-I (IGF-I). Moving further, this pipeline guide features drug profiles for the pipeline products which include, product description, R&D brief, licensing & collaboration details, MoA & other evolving activities. It includes AP-102, atesidorsen sodium, COR-005, FP-002 , IONIS-GHRLRx ITF-2984, L-779976, octreotide acetate, octreotide acetate long acting, octreotide acetate SR, pasireotide ER, Neuroendocrine Tumors, Somadex, SXN-101959.

In the later part, the report provides an overview of key players involved in therapeutic development for Acromegaly and also features their dormant as well as discontinued projects. They are as follows: Aegis Therapeutics LLC, Chiasma Inc, Dauntless Pharmaceuticals Inc, Amryt Pharma plc, Strongbridge Biopharma plc, DexTech Medical AB, Antisense Therapeutics Ltd., Glide Pharmaceutical Technologies Ltd., Daewoong Pharmaceutical Co. Ltd., Midatech Pharma Plc, Silence Therapeutics Plc., Novartis AG and Others.

By the above major information, Acromegaly (Hormonal Disorders) pipeline guide helps buyers in identifying and tracking emerging players in the market and their portfolios enhance policymaking capabilities and help to create effective counter-strategies to gain competitive advantage.

Click here to get more info with TOC in a PDF Format :

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top